ATC 0065
目录号 : GC10994
MCH1 antagonist,potent and selective
Cas No.:510732-84-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ATC0065 is a selective and potent antagonist of the melanin-concentrating hormone receptor 1 (MCH1) with IC50 of 15.7 nM. This component also displays affinity for 5-HT1A and 5-HT2B receptors with IC50 of 62.9nM and 266 nM respectively.
Melanin-concentrating hormone receptor (MCH1), a member of the G protein-coupled receptor family 1, is an integral plasma membrane protein which binds melanin-concentrating hormone. The protein can inhibit cAMP accumulation and stimulate intracellular calcium flux, and is probably involved in the neuronal regulation of food consumption.
In vitro assay, ATC0065 bounds with high affinity to the MCH-R1 with IC50 value of 16 nMand showed good metabolic stability in liver microsomes isolated from human and rat 1.
In rodents, ATC0065 is potent and orally active MCHR1 antagonists with anxiolytic and antidepressant activity. ATC0065 treatmetn significantly reversed swim stress-induced anxiety in the stress-induced hyperthermia in mice and elevated plus-maze test in rats2. However, ATC0065 did not affect spontaneous locomotor activity or rotarod performance in rats 2.
References:
1. Kanuma K, Omodera K, Nishiguchi M, et al. Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorganic & medicinal chemistry. 2006;14(10):3307-3319.
2. Chaki S, Funakoshi T, Hirota-Okuno S, et al. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. The Journal of pharmacology and experimental therapeutics. 2005;313(2):831-839.
| Cas No. | 510732-84-0 | SDF | |
| 化学名 | N2-((1r,4r)-4-((4-bromo-2-(trifluoromethoxy)phenethyl)amino)cyclohexyl)-N4,N4-dimethylquinazoline-2,4-diamine dihydrochloride | ||
| Canonical SMILES | BrC1=CC=C(C(OC(F)(F)F)=C1)CCN[C@@H](CC2)CC[C@H]2NC3=NC4=CC=CC=C4C(N(C)C)=N3.Cl.Cl | ||
| 分子式 | C25H29BrF3N5O.2HCl | 分子量 | 625.35 |
| 溶解度 | Soluble in DMSO | 储存条件 | Desiccate at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5991 mL | 7.9955 mL | 15.991 mL |
| 5 mM | 0.3198 mL | 1.5991 mL | 3.1982 mL |
| 10 mM | 0.1599 mL | 0.7996 mL | 1.5991 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet